Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VR1K
|
|||
| Drug Name |
1,2-diamino cyclopentane-based derivative 3
|
|||
| Synonyms |
PMID26593218-Compound-25
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
TAKEDA CAMBRIDGE LIMITED TAKEDA PHARMACEUTICAL COMPANY LIMITED
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H23N3O3S
|
|||
| Canonical SMILES |
COC1=C(C(=CC=C1)OC)C(=O)NC2CCCC2NC3=NC4=CC=CC=C4S3
|
|||
| InChI |
1S/C21H23N3O3S/c1-26-16-10-6-11-17(27-2)19(16)20(25)22-13-8-5-9-14(13)23-21-24-15-7-3-4-12-18(15)28-21/h3-4,6-7,10-14H,5,8-9H2,1-2H3,(H,22,25)(H,23,24)/t13-,14+/m0/s1
|
|||
| InChIKey |
PQSRJJBKNVQRDI-UONOGXRCSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Orexin receptor type 1 (HCRTR1) | Target Info | Antagonist | [1] |
| Orexin receptor type 2 (HCRTR2) | Target Info | Antagonist | [1] | |
| Target's Patent Info | Orexin receptor type 1 (HCRTR1) | Target's Patent Info | [1] | |
| Orexin receptor type 2 (HCRTR2) | Target's Patent Info | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | G alpha (q) signalling events | |||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.